Home Search
"life science" - search results
If you're not happy with the results, please do another search
Latest Deals: 23-29 April 2003
The AltAssets weekly round up of deals done across the world. This week there were 71 active investors in 31 deals and three exits across nine sectors, compared to 133 active investors in 47 deals and two exits the previous week…
Deals update: European deal flow slows over Easter break
Short working weeks and Easter holidays took their toll on European deal flow with the volume of private equity investments falling slightly from the previous week, according to AltAssets deals data.
BML launches E150m life sciences fund
Bioscience Managers Limited, (BML), has announced the launch of its fund management business focused on the life sciences sector. The E150m debut fund will be managed by a six strong team and will invest in European mid-stage life science companies.
gamma capital partners holds initial close for Austrian tech VC fund
Austrian gamma capital partners has announced an initial close of E10m for its technology venture fund gamma II. The fund, which was launched six months ago, will target high-tech companies in a variety of sectors including life sciences and electronics in Austria and in neighbouring countries.
Deals update: Private equity investment activity remains subdued
Private equity investment activity on both sides of the Atlantic remained fairly subdued in the latest week, according to AltAssets deals data. There were 48 deals and one exit in the week ending 8 April, compared with 46 deals and eight exits in the preceding week.
Latest Deals: 01 – 08 April 2003
The AltAssets weekly round up of deals done across the world. This week there were 109 active investors in 48 deals and one exit across 14 sectors, compared to 115 active investors in 46 deals and eight exits the previous week…
US biotech specialist MPM announces its largest exit to date with Idenix sale
US biotech venture specialist MPM Capital has announced its largest portfolio exit to date with the sale of its interest in Idenix Pharmaceuticals to Novartis Pharma. Novartis will pay shareholders $255m for a controlling share of the company, rising to more than $600m if the firm's drug candidates meet a series of milestones
Trends: March 2003
UK ranks top private equity market in Europe for tax and legal environment, European fundraising slows but investment creeps up, exit conditions bleakest for decades, French private equity investment figures up…
North America: March 2003
CalPERS discloses private equity data, Onex Corp establishes $1.5bn co-investment fund, Railroad pension plan to invest in private equity, Ohio seeks manager…
Deals Update: Investment activity steady but exits gather pace
Private equity investment activity continued at its steady and unremarkable level in the latest week but there was a marked improvement in exit activity, according to the latest AltAssets deals data.